Novartis NOVN 2.84%increase; up pointing triangle shares fell after the Swiss drugmaker said an experimental medicine failed to reduce cardiovascular risk in a late-stage clinical trial.
Shares in Novartis were down 3.2% in European morning trading Monday, reducing year-to-date gains to 14%.
Copyright ©2026 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8